PT Kalbe Farma Tbk (PTKFF)
0.0524
0.00 (0.00%)
USD |
OTCM |
Aug 26, 16:00
PT Kalbe Farma Enterprise Value : 2.219B for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 2.219B |
| August 25, 2026 | 2.219B |
| August 24, 2026 | 2.219B |
| August 21, 2026 | 2.219B |
| August 20, 2026 | 2.219B |
| August 19, 2026 | 1.669B |
| August 18, 2026 | 1.669B |
| August 17, 2026 | 1.669B |
| August 14, 2026 | 1.669B |
| August 13, 2026 | 1.669B |
| August 12, 2026 | 1.669B |
| August 11, 2026 | 1.669B |
| August 10, 2026 | 1.669B |
| August 07, 2026 | 1.669B |
| August 06, 2026 | 1.669B |
| August 05, 2026 | 1.669B |
| August 04, 2026 | 1.669B |
| August 03, 2026 | 1.669B |
| July 31, 2026 | 1.669B |
| July 30, 2026 | 1.669B |
| July 29, 2026 | 1.669B |
| July 28, 2026 | 1.669B |
| July 27, 2026 | 1.669B |
| July 24, 2026 | 1.669B |
| July 23, 2026 | 1.669B |
| Date | Value |
|---|---|
| July 22, 2026 | 1.669B |
| July 21, 2026 | 1.669B |
| July 20, 2026 | 1.669B |
| July 17, 2026 | 1.669B |
| July 16, 2026 | 1.669B |
| July 15, 2026 | 1.669B |
| July 14, 2026 | 1.669B |
| July 13, 2026 | 1.669B |
| July 10, 2026 | 1.669B |
| July 09, 2026 | 1.669B |
| July 08, 2026 | 1.669B |
| July 07, 2026 | 1.669B |
| July 06, 2026 | 1.669B |
| July 02, 2026 | 1.669B |
| July 01, 2026 | 1.669B |
| June 30, 2026 | 1.669B |
| June 29, 2026 | 1.656B |
| June 26, 2026 | 1.656B |
| June 25, 2026 | 1.656B |
| June 24, 2026 | 1.656B |
| June 23, 2026 | 1.656B |
| June 22, 2026 | 1.656B |
| June 18, 2026 | 1.656B |
| June 17, 2026 | 1.656B |
| June 16, 2026 | 1.781B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| AstraZeneca PLC | 542.01B |
| ANI Pharmaceuticals, Inc. | 1.947B |
| Corcept Therapeutics, Inc. | 12.63B |
| Veru, Inc. | 24.63M |
| Avadel Pharmaceuticals Plc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 52.51M |
| Revenue (Quarterly) | 559.49M |
| Total Expenses (Quarterly) | 508.65M |
| EPS Diluted (Quarterly) | 0.0011 |
| Gross Profit Margin (Quarterly) | 35.90% |
| Profit Margin (Quarterly) | 9.39% |
| Earnings Yield | 8.97% |
| Operating Earnings Yield | 11.45% |
| Normalized Earnings Yield | 8.970 |